Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.
Lancet. 2021 Feb 27;397(10276):839-852. doi: 10.1016/S0140-6736(21)00389-5.
Endometriosis is a common disease affecting 5-10% of women of reproductive age globally. However, despite its prevalence, diagnosis is typically delayed by years, misdiagnosis is common, and delivery of effective therapy is prolonged. Identification and prompt treatment of endometriosis are essential and facilitated by accurate clinical diagnosis. Endometriosis is classically defined as a chronic, gynaecological disease characterised by endometrial-like tissue present outside of the uterus and is thought to arise by retrograde menstruation. However, this description is outdated and no longer reflects the true scope and manifestations of the disease. The clinical presentation is varied, the presence of pelvic lesions is heterogeneous, and the manifestations of the disease outside of the female reproductive tract remain poorly understood. Endometriosis is now considered a systemic disease rather than a disease predominantly affecting the pelvis. Endometriosis affects metabolism in liver and adipose tissue, leads to systemic inflammation, and alters gene expression in the brain that causes pain sensitisation and mood disorders. The full effect of the disease is not fully recognised and goes far beyond the pelvis. Recognition of the full scope of the disease will facilitate clinical diagnosis and allow for more comprehensive treatment than currently available. Progestins and low-dose oral contraceptives are unsuccessful in a third of symptomatic women globally, probably as a result of progesterone resistance. Oral gonadotropin-releasing hormone (GnRH) antagonists constitute an effective and tolerable therapeutic alternative when first-line medications do not work. The development of GnRH antagonists has resulted in oral drugs that have fewer side-effects than other therapies and has allowed for rapid movement between treatments to optimise and personalise endometriosis care. In this Review, we discuss the latest understanding of endometriosis as a systemic disease with multiple manifestations outside the parameters of classic gynaecological disease.
子宫内膜异位症是一种常见疾病,影响全球 5-10%的育龄妇女。然而,尽管其患病率很高,但诊断通常会延迟数年,误诊很常见,有效的治疗也会延长。通过准确的临床诊断,识别和及时治疗子宫内膜异位症至关重要。子宫内膜异位症经典定义为一种慢性妇科疾病,其特征是子宫内膜样组织出现在子宫外,被认为是由逆行性月经引起的。然而,这种描述已经过时,不再反映疾病的真实范围和表现。临床表现多种多样,盆腔病变的存在具有异质性,女性生殖系统外疾病的表现仍知之甚少。子宫内膜异位症现在被认为是一种全身性疾病,而不仅仅是主要影响盆腔的疾病。子宫内膜异位症影响肝脏和脂肪组织的代谢,导致全身炎症,并改变大脑中的基因表达,导致疼痛敏化和情绪障碍。疾病的全部影响尚未完全被认识,其影响远远超出盆腔。认识到疾病的全部范围将有助于临床诊断,并允许提供比目前更全面的治疗。孕激素和低剂量口服避孕药在全球三分之一有症状的女性中无效,可能是由于孕激素抵抗。当一线药物无效时,口服促性腺激素释放激素(GnRH)拮抗剂构成一种有效且耐受良好的治疗选择。 GnRH 拮抗剂的开发导致了具有较少副作用的口服药物,并且允许在治疗之间快速移动以优化和个性化子宫内膜异位症的护理。在这篇综述中,我们讨论了子宫内膜异位症作为一种具有多种表现的全身性疾病的最新理解,超出了经典妇科疾病的范围。